modifying anti-rheumatic drugs (DMARDs) or to both DMARDs and anti-TNFs received the RA RTX regimen (1gx2). The clinical outcome measure was moderate/good EULAR response at 24 weeks. Responding patients were eligible to re-treatment with RTX upon disease exacerbation after a minimum of 48 weeks. Costs of RTX treatment (drug acquisition & administration) were compared to average costs of the spared anti-TNFs (infliximab, etanercept or adalimumab) that would have been provided otherwise to each patient until RTX re-treatment or end of follow-up (FU) . Prices are based on Israeli tariff before VAT. RESULTS: A total of 108 patients were enrolled. Sixty-seven DMARDs failures (62%), 41 DMARDs and anti-TNF failures (38%). At time of analysis (January 2008), 89 patients completed a minimum of 24 weeks follow-up (FU). Three dropped out in less than 24 weeks. Median FU: 75 weeks. 35/89 patients (39%) received re-treatment with RTX at a median of 63 weeks. A total of 37/89 patients (42%) were (at time of analysis) still on FU with no other treatment (median FU: 93wks). Average cost in Israel of anti-TNF treatment: NIS1955 (~560$)/week Cost of RTX (2g): NIS34,448 (~$9,840). The total saving per patient (up to data cutoff) results in NIS85, 258 (~$24, 360) . Overall cost saving during this period for 92 patients was NIS7,844 million (~$2,241,120). This sum is still an underestimation since 42% of the patients still require no further treatment, and continue to spare anti-TNF therapy. CONCLU-SIONS: From the payer perspective, RTX treatment is a significant cost-saving alternative for patients with RA in the Israeli public health care setting.
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COST OF RHEUMATOID ARTHRITIS MODEL PER LEVEL OF DISEASE ACTIVITY IN FRANCE
Beresniak A 1 , Gossec L 2 , Goupille P 3 , Saraux A 4 , Bamberger M 5 , Bregman B 5 1 LIRAES, Paris Descartes University, Paris, France and Data Mining International, Geneva, Switzerland, 2 Cochin Hospital, Paris, France, 3 CHRU de Tours-Université François Rabelais, Tours, France, 4 Hôpital de la Cavale Blanche, Brest, France, 5 Bristol-Myers Squibb, Rueil-Malmaison, France OBJECTIVES: RA is a chronic disease associated with a significant use of health care resources, imposing a substantial economic burden to patients, health insurance and to society in France. The objective of the present study was to assess the use of direct medical resources excluding drug costs by RA patients in France and to derive original costing data per level of disease activity. METHODS: An advanced standard costing approach was performed in collaboration with a panel of expert clinicians highly experienced in the management of RA in France. Four categories of disease activity were defined according to DAS28 thresholds: patients (pts) achieving remission (DAS <2.6), pts not achieving remission (DAS Ն2.6), pts achieving low disease activity state (LDAS; DAS Յ3.2) and pts not achieving LDAS (DAS >3.2). Eight resource utilization items were defined: medical visits, laboratory tests, hospitalization, imaging, physiotherapy, nursing, adaptive aids and transportation. Resource utilization and unit costs from the national payer perspective were collected and simulated using distribution ranges for each item. Using a simulation model, a computation of all costs distributions was performed to estimate the overall costs per six months over a 2-year time horizon. RESULTS: Direct medical costs were estimated per disease activity level. For pts achieving remission during the first 6 months, about 90% generated costs under €1000, with costs estimated at €771 (SD = 199) per 6 months and €511 (SD = 162) for each subsequent 6 months (p < 0.001). For pts not achieving remission per 6 months, about 85% gen-erated costs under €1500, with costs estimated at €1159 per 6 months (SD = 339). For pts achieving LDAS, costs were estimated at €905 (SD = 263) per 6 months and €696 (SD = 240) for each subsequent 6 months (p < 0.001). For pts not achieving LDAS, costs were estimated at €1215 per 6 months (SD = 405). Key costs drivers were medical visits, laboratory tests and transportation. CONCLUSIONS: This cost of illness assessment provides precise and current estimates of medical direct costs per RA disease activity in France, confirming that RA imposes a substantial economic burden. The findings suggest that achieving LDAS or remission is associated with substantially lower RA medical costs.
PMS29 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA IN SPANISH PATIENTS
Lamotte M 1 , Maugars Y 2 , De Vos C 1 , Girard L 3 , Le Lay K 4 , Taieb C 4 1 IMS Health, Brussels, Belgium, 2 Hotel Dieu, Nantes, France, 3 IMS Health, Nantes, France, 4 Pierre Fabre, Boulogne, France OBJECTIVES: To estimate the cost savings in outpatient medical resource use associated with diagnosing fibromyalgia during the four years after fibromyalgia diagnosis. METHODS: A questionnaire was created based on the medical resources use from 2260 patients diagnosed with FM between January 1998 and March 2003 in the General Practice Research Database (FF-GPRD) in United-Kingdom. Local experts were asked to compare their own clinical practice to UK prescriptions and resource use, over a period of four years before diagnosis to four plus years after diagnosis using one year cross-sections. Poisson loglinear regression models, published for the UK, allowed to estimate the medical resources consumed if no diagnosis had been established. The impact of diagnosis was evaluated for each of these medical resources. Costs were calculated by multiplying resource use with corresponding Spanish unit costs (€; 2008; both public health care payer perspective and societal perspective including patient co-payments). RESULTS: This study confirms previously published results obtained for the UK and France: whereas costs gradually increase before diagnosis, a stagnation in costs increase occurs in the year after diagnosis, subsequently followed by a moderate decrease afterwards. The savings made as a result of fibromyalgia diagnosis add up to €421 per patient and per year from the health care system perspective and €432 from a societal point of view. Diagnostic tests, referrals to specialists, GP visits and drugs represent respectively 42%, 29%, 15% and 14% of these savings, CONCLUSIONS: Compared to a diagnosed fibromyalgia patient, a not diagnosed patient in Spain represents an incremental cost of €421 from the health care payer perspective. Abstracts A545 and referrals. over a period of 4 years before diagnosis to 4 years-plus after diagnosis using one year intervals. Poisson loglinear regression models, published for the UK, allowed to estimate the medical resources consumed if no diagnosis had been established. The impact of diagnosis was evaluated for each of these medical resources. Costs were calculated by multiplying resource use with corresponding French unit costs (€; 2007; both public health care payer perspective and societal perspective including patient co-payments). RESULTS: This study confirms previously published results for the UK: whereas costs gradually increase before diagnosis, a stagnation in costs increase occurs in the year after diagnosis, subsequently followed by a moderate decrease afterwards. The same trend was observed whether the panel consisted of GP or rheumatologists. The savings made as a result of fibromyalgia diagnosis add up to €126 per patient and per year in France from the health care system perspective and €184 from a societal perspective. GP visits, diagnostic tests, drugs and referrals to specialists represent respectively 57%, 23%, 12% and 8% of these savings. CONCLUSIONS: Compared to a diagnosed fibromyalgia patient, a not diagnosed patient represents an incremental cost of €126 from the public health care payer perspective, mainly due to medical nomadism and multiplication of investigations and prescriptions.
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OSTEOARTHRITIS AND JOB ABSENTEEISM COSTS: EVIDENCE FROM U.S. NATIONAL SURVEY DATA
Kotlarz H 1 , Gunnarsson C 2 , Rizzo J 3 1 DePuy Orthopaedics, Warsaw, IN, USA, 2 S2 Statistical Solutions, Inc, Cincinnati, OH, USA, 3 Stony Brook University, Stony Brook, NY, USA OBJECTIVES: Osteoarthritis is a common chronic illness affecting 20 million persons in the United States. To date, however, there is very little evidence quantifying the effects of osteoarthritis on the cost of job absenteeism and presenteeism. Yet such information would be useful to employers in designing health benefits for their employees. METHODS: Using data from the Medical Expenditure Panel Survey (MEPS), a large nationallyrepresentative database from the United States, this study performs bivariate and multivariate analyses to quantify the relationship between osteoarthritis and annual job absenteeism costs to employers. Individual estimates by occupation, as well as nationally-aggregated measures, will be provided. RESULTS: We find that osteoarthritis significantly increases job absenteeism by 2.39 days per annum (p < 0.01), raising job absenteeism costs by $478 per employee. These differences vary by occupation, and are largest for workers in the service sector ($1070), office workers ($922) and equipment operators ($1084). Subjects working in managerial, sales, and professional occupations miss on average half as many days of work from osteoarthritis than do subjects in traditionally blue-collar occupations. Job absenteeism costs from osteoarthritis are larger for females ($554) than for males ($342). CONCLUSIONS: These results indicate that job absenteeism due to osteoarthritis is pervasive and are an inherent cost in the work place. Employers may realize substantial productivity gains in their workers by promoting alternative treatment regimens to mitigate the debilitating effects of this disease.
